Arvinas (NASDAQ:ARVN) Given Overweight Rating at Cantor Fitzgerald
Arvinas (NASDAQ:ARVN) Given Overweight Rating at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Arvinas (NASDAQ:ARVN – Get Rating) in a research note published on Wednesday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Arvinas' FY2022 earnings at ($4.84) EPS and FY2023 earnings at ($6.19) EPS.
據PriceTargets.com報道,康託·菲茨傑拉德在週三上午發佈的一份研究報告中重申了他們對阿維納斯(納斯達克代碼:ARVN-GET評級)股票的增持評級。康託·菲茨傑拉德還發布了對Arvinas 2022財年每股收益(4.84美元)和2023財年每股收益(6.19美元)的預期。
Several other brokerages have also recently commented on ARVN. Credit Suisse Group lowered their target price on shares of Arvinas from $98.00 to $78.00 and set an outperform rating on the stock in a report on Friday, August 5th. HC Wainwright lowered their target price on shares of Arvinas from $135.00 to $90.00 and set a buy rating on the stock in a report on Friday, August 5th. Oppenheimer lowered their target price on shares of Arvinas from $108.00 to $102.00 and set an outperform rating on the stock in a report on Monday, August 8th. SVB Leerink lowered their target price on shares of Arvinas from $91.00 to $89.00 and set an outperform rating on the stock in a report on Friday, August 5th. Finally, Jefferies Financial Group began coverage on shares of Arvinas in a research note on Tuesday, June 21st. They issued a hold rating and a $42.00 price objective on the stock. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, Arvinas currently has a consensus rating of Moderate Buy and an average price target of $82.13.
其他幾家券商最近也對ARVN發表了評論。瑞士信貸集團在8月5日週五的一份報告中將Arvinas的股票目標價從98.00美元下調至78.00美元,並對該股設定了表現優於大盤的評級。在週五的一份報告中,HC Wainwright將Arvinas的股票目標價從135.00美元下調至90美元,並對該股設定了買入評級。奧本海默在8月8日週一的一份報告中將阿維納斯的目標價從108.00美元下調至102.00美元,並對該股設定了表現優於大盤的評級。SVB Leerink在8月5日週五的一份報告中將Arvinas的目標價從91.00美元下調至89.00美元,並對該股設定了表現優於大盤的評級。最後,傑富瑞金融集團在6月21日星期二的一份研究報告中開始報道Arvinas的股票。他們對該股發佈了持有評級和42.00美元的目標價。3名分析師對該股的評級為持有,13名分析師給予該公司買入評級。根據MarketBeat.com的數據,Arvinas目前的共識評級為中等買入,平均目標價為82.13美元。
Arvinas Stock Down 2.0 %
Arvinas股價下跌2.0%
Shares of ARVN stock opened at $42.06 on Wednesday. The firm has a 50 day moving average price of $48.80 and a two-hundred day moving average price of $51.67. The company has a market capitalization of $2.24 billion, a PE ratio of -9.43 and a beta of 2.06. Arvinas has a 12-month low of $34.90 and a 12-month high of $97.33.
ARVN股票週三開盤報42.06美元。該公司的50日移動均線價格為48.80美元,200日移動均線價格為51.67美元。該公司市值22.4億美元,市盈率為-9.43,貝塔係數為2.06。Arvinas的12個月低點為34.90美元,12個月高位為97.33美元。
Insiders Place Their Bets
內部人士下注
In other Arvinas news, insider Ronald Peck sold 1,258 shares of the business's stock in a transaction on Friday, August 12th. The shares were sold at an average price of $68.99, for a total transaction of $86,789.42. Following the sale, the insider now owns 8,154 shares of the company's stock, valued at $562,544.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.78% of the company's stock.
在阿維納斯的其他消息中,內部人士羅納德·佩克在8月12日星期五的一次交易中出售了1258股該公司的股票。這些股票的平均價格為68.99美元,總成交金額為86,789.42美元。出售後,這位內部人士現在擁有該公司8,154股股票,價值562,544.46美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過這個環節。內部人士持有該公司2.78%的股份。
Institutional Trading of Arvinas
阿維納斯的機構交易
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. lifted its holdings in shares of Arvinas by 12.7% during the fourth quarter. Invesco Ltd. now owns 543,797 shares of the company's stock worth $44,668,000 after purchasing an additional 61,087 shares during the period. Nordea Investment Management AB acquired a new position in shares of Arvinas during the first quarter worth $245,000. Paradigm Biocapital Advisors LP lifted its holdings in shares of Arvinas by 83.0% during the first quarter. Paradigm Biocapital Advisors LP now owns 491,333 shares of the company's stock worth $33,067,000 after purchasing an additional 222,814 shares during the period. Versor Investments LP lifted its holdings in shares of Arvinas by 421.9% during the first quarter. Versor Investments LP now owns 21,921 shares of the company's stock worth $1,475,000 after purchasing an additional 17,721 shares during the period. Finally, Banque Pictet & Cie SA lifted its holdings in shares of Arvinas by 4.0% during the first quarter. Banque Pictet & Cie SA now owns 28,818 shares of the company's stock worth $1,940,000 after purchasing an additional 1,115 shares during the period. Institutional investors own 91.20% of the company's stock.
一些對衝基金和其他機構投資者最近調整了對該股的持有量。景順在第四季度增持了12.7%的Arvinas股票。景順股份有限公司目前持有543,797股該公司股票,價值44,668,000美元,在此期間又購買了61,087股。北歐投資管理公司在第一季度收購了價值24.5萬美元的Arvinas股票的新頭寸。第一季度,Parample BioCapital Advisors LP增持了83.0%的Arvinas股票。在此期間額外購買了222,814股後,範式BioCapital Advisors LP現在擁有491,333股公司股票,價值33,067,000美元。Versor Investments LP在第一季度增持了421.9%的Arvinas股票。Versor Investments LP現在擁有21,921股該公司股票,價值1,475,000美元,在此期間又購買了17,721股。最後,Banque Pictet&Cie SA在第一季度增持了4.0%的Arvinas股票。Banque Pictet&Cie SA現在持有28,818股該公司股票,價值1,940,000美元,在此期間又購買了1,115股。機構投資者持有該公司91.20%的股票。
About Arvinas
關於阿維納斯
(Get Rating)
(獲取評級)
Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.
Arvinas,Inc.是一家臨牀階段的生物製藥公司,致力於發現、開發和商業化降解致病蛋白的療法。其主要候選產品包括針對雄激素受體(AR)蛋白的轉移性去勢耐藥前列腺癌(MCRPC)治療處於I期臨牀試驗的靶向嵌合體(PROTAC)蛋白降解劑Bavdecalutide;用於治療ER陽性/HER2陰性轉移性乳腺癌患者的PROTAC蛋白降解劑ARV-471;以及用於治療男性mCRPC的研究中口服可用PROTAC蛋白降解劑ARV-766。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Arvinas (ARVN)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 免費獲取StockNews.com關於Arvinas的研究報告(ARVN)
- MarketBeat:回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性?
- CrowdStrike是否會從增加每股收益指引中獲得提振?
- 小盤股的裁員是樓市的晴雨表嗎?
- 好市多盈利後價格疲軟是買入的好時機嗎?
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿維納斯日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Arvinas和相關公司的最新新聞和分析師評級的每日簡要摘要。